|CNAT -- USA Stock|| |
USD 5.99 0.50 7.70%
Dr. Steven J. Mento, Ph.D., is appointed as President, Chief Executive Officer, Director of Conatus Pharmaceuticals Inc. He is one of cofounders and has served as President and Chief Executive Officer and as a member of board of directors since July 2005. From July 2005 until December 2012, he also served as chairman of the board of directors. He has over 30 years of combined experience in the biotechnology and pharmaceutical industries. From 1997 to 2005, he was President, Chief Executive Officer and a member of the Board of Directors of Idun Pharmaceuticals, Inc. He guided Idun during its transition from a discovery focused organization to a drug development company with multiple products in or near human clinical testing. In April 2005, Idun was sold to Pfizer Inc. Previously, he served as President of Chiron Viagene, Inc., and Vice President of Chiron Corporationrationration from 1995 to 1997. He was Vice President of RD at Viagene from 1992 to 1995. Prior to Viagene, he held various positions at American Cyanamid Company from 1982 to 1992. His last position was Director of Viral Vaccine Research and Development at LederlePraxis Biologicals, a business unit of American Cyanamid. He serves on the boards of directors of BIOCOM, the Biotechnology Industry Organization, BIO Emerging Company Section Governing Body, BIO Health Section Governing Body, Sangamo Biosciences, Inc., and various academic and charitable organizations
Age: 65 CEO Since 2017
Mento holds a B.A. in Microbiology from Rutgers College, and an M.S. and Ph.D. both in Microbiology from Rutgers University.